Wed, Apr 23, 2014, 9:28 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • hakujinchad hakujinchad Nov 11, 2012 6:25 PM Flag

    NCE denied (hopefully, better than delay), then stock rallies because... (& detailed NCE explanation)

    Smart $ has known from the get-go that NCE doesn't factor into squat w/ the existing patent port and future Anchor Indication. They have just used this in order to suppress the stock, and create volatility where there has been no near term catalyst to otherwise cause trading noise.

    Why won't NCE be granted NCE? According to some very smart individuals whom I've had the pleasure of speaking to, it's very simple:

    People are getting lessons in structural isomerism and using this as their basis for positive NCE.   Here's the deal, EPA or eicosapentaeonic acid in both Vascepa and Lovaza come from the same source; the acids are produced in algae, consumed by fish and harvested by humans.  The biochemical processes which produce things like fatty acids have been hardwired into nature for perhaps many hundreds of millions of years: they produce the same fatty acid with the same conformation over and over; the configurational isomer is stable (cis-trans isomerization).  The chemical process used to produce the ester won't change the isomerization.  More importantly, Amarin filed a 505(b)(2) application to the FDA; this type of application almost always presupposes that clinical data already exist, but to which the company doesn't have the right of reference, that can be used to support safety and efficacy.  Amarin was required to run truncated clinical trials to support its NDA.  The active ingredient, the eicosapentaeonic ester, where the active ingriedient is likely eicosapentaeonate, is identical in both Vascepa and Lovaza.  Vascepa has just a much purer form, but it is the same molecule, form the same biosource.  It will have the same conformational isomeric configuration--unless evolution had a sudden burst in the last few years, in which case, since Lovaza comes from the same biopool, it will have a new configuration too!  If Amarin really did have a different conformer, it would have filed a patent to protect it--it hasn't.  The patent would give the company up to 20 years of protection: once again, patents are more important in this case than is any guarantee from the FDA.

    I go all in this week and sit on it until I get double return. Good luck!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMRN
1.62-0.01(-0.61%)Apr 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.